Bilousova Natalia, Tkachenko Natalia, Kozhuharyova Nataliia, Dolzhenko Maryna
Pharmaceutical and Preventive Medicine Faculty, Department of Pharmacy, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Faculty of Pharmacy, Department of Management and Economics of Pharmacy, Zhaporizhzhia State Medical and Pharmaceutical University, Zaporizhia, Ukraine.
J Pharm Policy Pract. 2025 Mar 11;18(1):2470841. doi: 10.1080/20523211.2025.2470841. eCollection 2025.
The issue of population access to medicines is relevant worldwide. Pandemics, natural disasters, wars negatively affect the population's access to medicines, as emphasised by the WHO and the UN.
The analysis of scientific publications in the Ukrainian scientometric databases (NRAT, OUCI); Scopus, Web of Science, Pubmed, Medline, BMJ and Embase; the legal field for providing medical care to patients with CHD and comorbid conditions and its pharmaceutical component. The EML of Europe and Ukraine are compared; the clinical recommendations and pharmacotherapy of European/American Societies of Cardiology (ESC/AHA) and Ukrainian for patients with CHD and comorbid conditions are compared.
The prices of medicines that are not part of the 'Affordable Medicines' program and are included in the EML lists were analysed; their availability for Ukrainian patients in wartime conditions was determined. The legal field of providing medical care to patients with CHD and comorbid conditions has been formed. It was established that not all medicines specified in the EML are registered on the territory of Ukraine and included in the Program of Medical Guarantees (PMG).
The PMG includes most of the EML medicines. The modern pharmacotherapy of CHD and comorbid conditions has a positive impact on the budget of the health care system in clinical practice proposed by the ESC/AHA was determined. The lists of medicines in the PMG in Ukraine, need to be revised on the basis of the Health Technology Assessment for further inclusion in the state program 'Affordable Medicines' for long-term use by patients with CHD and comorbid conditions. These measures will improve the quality of pharmaceutical care for these patients.
药品的人群可及性问题在全球范围内都很重要。世界卫生组织和联合国强调，大流行病、自然灾害、战争对人群获取药品产生负面影响。
分析乌克兰科学计量数据库（NRAT、OUCI）；Scopus、科学网、PubMed、Medline、《英国医学杂志》和Embase中的科学出版物；为冠心病及合并症患者提供医疗服务的法律领域及其药物组成部分。比较欧洲和乌克兰的基本药物清单；比较欧洲/美国心脏病学会（ESC/AHA）和乌克兰针对冠心病及合并症患者的临床建议和药物治疗方法。
分析了未纳入“平价药品”计划但列入基本药物清单的药品价格；确定了这些药品在战时条件下对乌克兰患者的可及性。已形成了为冠心病及合并症患者提供医疗服务的法律领域。已确定并非基本药物清单中列出的所有药品都在乌克兰境内注册并纳入医疗保障计划（PMG）。
医疗保障计划涵盖了大部分基本药物清单中的药品。确定了ESC/AHA提出的冠心病及合并症现代药物治疗方法在临床实践中对医疗保健系统预算有积极影响。乌克兰医疗保障计划中的药品清单需要根据卫生技术评估进行修订，以便进一步纳入国家“平价药品”计划，供冠心病及合并症患者长期使用。这些措施将提高这些患者的药学服务质量。
